CD8A and neoplasm: An OV-mOX40L treatment also increases the infiltration of CD4+ T cells, decreases the tumor-infiltrating CD8+ T cell exhaustion, reduces FOXP3+ regulatory CD4+ T cells, and reprograms macrophages and neutrophils to a pro-inflammatory state (93).